ILD/CVID/GD | Sarcoid controls | p-value | |
Subjects | 20 | 60 | |
Age yrs | 44±17 | 43±11.5 | 0.89 |
Males/females | 11 (55)/9 (45) | 18 (30)/42 (70) | 0.04 |
Caucasian/black ethnicity | 18/2 | 49/11 | 0.5 |
Recurrent infections | 13 (65) | 3 (5) | <0.001 |
Autoimmune disease | 8 (40) | 1 (1.7) | <0.001 |
Crackles | 9 (45) | 1 (1.7) | <0.001 |
Splenomegaly | 15 (75) | 5 (8.3) | <0.001 |
Hepatomegaly | 10 (50) | 5 (8.3) | <0.001 |
Extrathoracic localisation | 19 (95) | 39 (65) | 0.009 |
Number of extrathoracic localisations | 2.4±1.3 | 1.3±1.3 | 0.002 |
PFTs | |||
Normal | 5 (25) | 11 (18.3) | 0.5 |
Obstructive syndrome | 2 (10) | 12 (20) | 0.4 |
Restrictive syndrome | 7 (35) | 11 (18) | 0.1 |
TL,CO impairment | 13 (65) | 44 (73) | 0.6 |
Blood lymphocyte count cells per mm3 | 1498±864 | 1374±547 | 0.57 |
Increased sACE | 14 (88) | 47 (78) | 0.55 |
BAL | |||
BAL lymphocyte count % | 37.3±15.3 | 27±21 | 0.08 |
CD4/CD8 T-cell ratio | 1.6±1.1 | 5.3±4 | <0.001 |
Data are presented as n, mean±sd or n (%), unless otherwise stated. PFT: pulmonary function test; TL,CO: transfer factor of the lung for carbon monoxide; sACE: serum angiotensin-converting enzyme; BAL: bronchoalveolar lavage. Bold indicates statistically significant p-values.